Gene
KRTAP5-8
Entrez Gene ID | 57830 (See on NCBI) |
Description | keratin associated protein 5-8 |
Gene Synonyms | KRTAP5-2, KRTAP5.8, UHSKerB |
Node consisting of this Gene | KRTAP5-8 KRTAP5-2 KRTAP5-11///KRTAP5-2///KRTAP5-10 KRTAP5-7///KRTAP5-8 |
Networks including this gene
GSE10797_top8000 - GSE10797 - SiGN-BN NNSR | Transcriptomes of breast epithelium and stroma in normal reduction mammoplasty and invasive breast cancer patients. |
GSE10810_top8000 - GSE10810 - SiGN-BN NNSR | Gene expression signatures in breast cancer distinguish phenotype charact., histological subtypes, and tumor invasivness |
GSE10972_top8000 - GSE10972 - SiGN-BN NNSR | Colon cancer |
GSE11135_top8000 - GSE11135 - SiGN-BN NNSR | The MILE (Microarray Innovations In LEukemia) study pre-phase |
GSE11151_top8000 - GSE11151 - SiGN-BN NNSR | Gene expression data from different types of renal tumors and normal kidneys |
GSE11582_top8000 - GSE11582 - SiGN-BN NNSR | Genetic Analysis of Human Traits In-Vitro: Drug Response and Gene Expression in Lymphoblastoid Cell Lines |
GSE11869_top8000 - GSE11869 - SiGN-BN NNSR | The genomic response of a human uterine endometrial adenocarcinoma cell line to 17alpha-ethynyl estradiol. |
GSE12470_top8000 - GSE12470 - SiGN-BN NNSR | Gene expression profiles of serous ovarian cancer samples |
GSE12790_top8000 - GSE12790 - SiGN-BN NNSR | Gene expression profiling of human breast cancers and cancer cell lines |
GSE13507_top8000 - GSE13507 - SiGN-BN NNSR | Predective Value of Prognosis-Related Gene Expression Study in Primary Bladder Cancer |
GSE14206_top8000 - GSE14206 - SiGN-BN NNSR | Analysis of ETS gene expression patterns uncovers novel ETS mediated gene silencing pathways in prostate cancers |
GSE14208_top8000 - GSE14208 - SiGN-BN NNSR | Clinical response of metastatic gastric cancer patients to cisplatin and fluorouracil (CF) combination chemotherapy |
GSE14210_top8000 - GSE14210 - SiGN-BN NNSR | Expression data from human endoscopic biopsy samples |
GSE15212_top8000 - GSE15212 - SiGN-BN NNSR | Identification and validation of NOL5A and RPS2 as potential therapeutic targtes in colorectal cancer |
GSE15641_top8000 - GSE15641 - SiGN-BN NNSR | Gene signatures of progression and metastasis in renal cell cancer |
GSE16237_top8000 - GSE16237 - SiGN-BN NNSR | Expression data of human neuroblastoma tissue samples |
GSE16987_top8000 - GSE16987 - SiGN-BN NNSR | A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis |
GSE17705_top8000 - GSE17705 - SiGN-BN NNSR | Endocrine Sensitivity Index Validation Dataset |
GSE17920_top8000 - GSE17920 - SiGN-BN NNSR | Expression data of diagnostic biopsy samples from Hodgkin lymphoma patients |
GSE18521_top8000 - GSE18521 - SiGN-BN NNSR | A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor: MAGP2 |
GSE19615_top8000 - GSE19615 - SiGN-BN NNSR | Integrated genomic and function characterization of the 8q22 gain |
GSE20189_top8000 - GSE20189 - SiGN-BN NNSR | A gene expression signature from peripheral whole blood for stage I lung adenocarcinoma |
GSE20257_top8000 - GSE20257 - SiGN-BN NNSR | Smoking-induced Disarray of the Apical Junctional Complex Gene Expression Architecture in the Human Airway Epithelium |
GSE20842_top8000 - GSE20842 - SiGN-BN NNSR | Mutated KRAS induces overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas |
GSE21501_top8000 - GSE21501 - SiGN-BN NNSR | A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma |
GSE22153_top8000 - GSE22153 - SiGN-BN NNSR | Gene Experssion Profiling-Based Identification of Molecular Subtypes in Stage IV Melanoma with Different Clinical Outcome (test set) |
GSE23991_top8000 - GSE23991 - SiGN-BN NNSR | Effect of zebularine on primary human liver cancer cell lines |
GSE25136_top8000 - GSE25136 - SiGN-BN NNSR | Optimizing molecular signatures for prostate cancer recurrence |
GSE26549_top8000 - GSE26549 - SiGN-BN NNSR | Gene Expression Profiling Predicts the Development of Oral Cancer |
GSE26712_top8000 - GSE26712 - SiGN-BN NNSR | A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer |
GSE27562_top8000 - GSE27562 - SiGN-BN NNSR | Expression data from human PBMCs from breast cancer patients and controls |
GSE2841_top8000 - GSE2841 - SiGN-BN NNSR | Expression Profiling of pheochromocytomas of various genetic origins |
GSE2912_top8000 - GSE2912 - SiGN-BN NNSR | Molecular classification of multiple myeloma |
GSE29288_top8000 - GSE29288 - SiGN-BN NNSR | Comparison between cell lines from 9 different cancer tissue (NCI-60) (Agilent WG platform) |
GSE3167_top8000 - GSE3167 - SiGN-BN NNSR | Classification of carcinoma in situ lesions in human bladder cancer |
GSE4115_top8000 - GSE4115 - SiGN-BN NNSR | Airway Epithelial Gene Expression Diagnostic for the Evaluation of Smokers with Suspect Lung Cancer |
GSE4122_top8000 - GSE4122 - SiGN-BN NNSR | Gene Expression Analysis of Ovarian Samples |
GSE5851_top8000 - GSE5851 - SiGN-BN NNSR | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
GSE6462_top8000 - GSE6462 - SiGN-BN NNSR | MCF7 dose response |
GSE6477_top8000 - GSE6477 - SiGN-BN NNSR | Expression data from different stages of plasma cell neoplasm |
GSE6691_top8000 - GSE6691 - SiGN-BN NNSR | Gene expression profiling of B lymphocytes and plasma cells from WaldenstrÖm’s macroglobulinemia. |
GSE6956_top8000 - GSE6956 - SiGN-BN NNSR | Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American Men |
GSE8581_top8000 - GSE8581 - SiGN-BN NNSR | Human Chronic Obstructive Pulmonary Disorder (COPD) Biomarker |
GSE9936_top8000 - GSE9936 - SiGN-BN NNSR | Expression data from human breast cancer cells (MCF-7) coexpressing ERalpha and Erbeta, treated with phytoestrogens |
GSE9992_top8000 - GSE9992 - SiGN-BN NNSR | Molecular and transcriptional characterization of chromosome 17p loss in chronic lymphocytic leukemia, experiment A |
(45 networks)